Search Results - "A. Carrato Mena"

Interim quality of life results from a real world European survey on the unmet needs of patients living with metastatic colorectal cancer (mCRC) by Maravic, Z., Wyrwicz, L., Karczmarek-Borowska, B., Horvath, A., Ruiz Casado, A., Carrato Mena, A., Muszbek, N., Rakonczai, P.

Get full text

Efficacy of trastuzumab-emtansina (T-DM1) in HER2-positive breast cancer (BC) with brain metastases (BM): A single institution experience by Martin Huertas, R., Lopez Miranda, E., Corral de la Fuente, E., Serrano Domingo, J.J., Fernandez Abad, M., Martinez, N., Guerra, E.M., Cortes Salgado, A., Gion Cortes, M., Carrato Mena, A.

Get full text

Symptoms at diagnosis of (metastatic) pancreatic adenocarcinoma ([m]PAC) in routine practice and frequency variation across Europe by Carrato Mena, A., Melisi, D., Westphalen, B., Mellbring, Å.B.C., Taieb, J., Prager, G., Macarulla Mercadé, T., esquermes, N.D., Ferreras, A., de Jong, F.

Get full text

Assessment and treatment of breakthrough cancer pain in Spain: A self-audit study by Lopez Lopez, R., Reina Zoilo, J.J., Monge, D., Caballero, F., Guillem Porta, V., Aranda Aguilar, E., Carrato Mena, A., Diaz Rubio, E., Garcia Foncillas, J., Feyjoo, M., Camps, C.

Get full text

Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase 3 RECOURSE trial by Longo-Muñoz, F., Argiles, G., Tabernero, J., Cervantes, A., Gravalos, C., Pericay, C., Gil-Calle, S., Mizuguchi, H., Carrato-Mena, A., Limón, M. L., Garcia-Carbonero, R.

“…Purpose TAS-102 is a combination of the thymidine-based nucleoside analog trifluridine and the thymidine phosphorylase inhibitor tipiracil. Efficacy and safety…”
Get full text

The quality oncology practice initiative program: Experience in Spain by Lopez Lopez, R., Anton Torres, A., Aranda Aguilar, E., Carrato Mena, A., Constenla Figueiras, M., Cruz Hernandez, J.J., Diaz Rubio, E., Feyjoo, M., Garcia Foncillas, J., Gascon, P.N., Guillem Porta, V., Lugo Cuan, I.S., Rogado, A., Camps, C.

Get full text

Safety and outcomes of self-expandable metal stents (SEMS) versus emergency surgery for acute colonic obstruction in metastatic colon cancer patients treated with bevacizumab (BV) by Pacheco-Barcia, V.E., Mondéjar Solís, R., Martínez-Sáez, O., Longo, F., Bermejo, E., Moreno, J.A., Marin, C., Correa, A., Maqueda, R., Rogado, J., García de Paredes, A., Rodriguez de Santiago, E., Pachón Olmos, V., Ferreiro Monteagudo, R., Rodriguez Garrote, M., Carrato Mena, A., Donnay, O., Martin Perez, E., Santander, C., Colomer Bosch, R.

Get full text

Clinical practice evaluation of opioids induced constipation management in oncologic patients: The EIO-50 project by Salvador Bofill, J., Guillem Porta, V., Feyjoo, M., Anton Torres, A., Aranda Aguilar, E., Camps, C., Carrato Mena, A., Constenla Figueiras, M., Cruz Hernandez, J.J., Diaz Rubio, E., Garcia Foncillas, J., Gascon, P.N., Lopez Lopez, R., Soler, B., Escobar, Y.

Get full text

Active study: undetected prevalence and clinical inertia in the treatment of breakthrough cancer pain (BTcP) by Camps Herrero, C., Reina Zoilo, J. J., Monge Martín, D., Caballero Martínez, F., Guillem Porta, V., Aranda Aguilar, E., Carrato Mena, A., Díaz-Rubio García, E., García-Foncillas López, J., Feijóo Saus, M., López López, R.

“…Aims To prove if there is clinical inertia in the identification and treatment of episodes of breakthrough cancer pain (BTcP), comparing actual results from…”
Get full text

Oncologist’s knowledge and implementation of guidelines for breakthrough cancer pain in Spain: CONOCE study by López López, R., Camps Herrero, C., Khosravi-Shahi, P., Guillem Porta, V., Carrato Mena, A., Garcia-Foncillas, J., Cruz Hernández, J. J., Gascón Vilaplana, P., Antón Torres, A., Diaz-Rubio, E., Feyjoo Saus, M., Aranda Aguilar, E.

“…Purpose Breakthrough cancer pain (BTcP) has been shown to be a prevalent and poor prognostic factor for oncologic patients, which remain under diagnosed and…”
Get full text

Cost-Effectiveness Analysis of Bevacizumab, Fotemustine and Extended-Dose Temozolomide in Patients with Recurrent Glioblastoma in Spain by Garcia Lopez, J.L, Rodriguez, Barrios J.M, Puig-Junoy, J, Carrato, Mena A

Get full text

513P Cyclin pathway in oligodendrogliomas IDH mut and 1p/19q codeleted by Salgado, M.A. Vaz, Sanchez, J.M. Sepulveda, Earl, J., Perez, A., Pian, H., Ruano, Y., Gutierrez, J., Mena, A. Carrato, Ley, L.L., Villamayor, M., López, V., Delfrade, I. Martínez, Albarrán, V., Chamorro-Perez, J., Rodriguez, D.I. Rosero, Morón, B.I., A.H. lain

Get full text

1658P Molecular subtyping of familial pancreatic ductal adenocarcinoma identifies novel pathogenic germline variants by Earl, J., Barreto, E., Rodriguez, M., Villalon López, J., Fuentes Mateos, R., Garcia García de Paredes, A., Sanjuanbenito, A., Lobo, E., Ruz-Caracuel, I., Muñoz Beltran, M., Ramos, E., Blaquez, J., Carrato Mena, A.

Get full text

1338P Cost-effectiveness and direct impact analysis of clinical research in the clinical approach of metastatic renal cell carcinoma and neuroendocrine tumors in a large public Spanish university hospital by García-Garro, S., Gajate Borau, P., Gómez de Salazar, E., Alonso Gordoa, T., Rodriguez Sagrado, M.Á., Molina Cerrillo, J., Manzano Espinosa, L., Bermejo Vicedo, T., Carrato Mena, A., Díez Gómez, J.J., Grande Pulido, E.

Get full text

1671P Treatment patterns and efficacy in patients (pt) with pancreatic cancer (PC) from the Spanish RETUD registry by Macarulla, T., Munoz Martin, A.J., Martinez de Castro, E., Castillo Trujillo, A.O., Cano Osuna, M.T., Fabregat, C., Vidal Tocino, R., Gallego Plazas, J., Ghanem, I., Ales Diaz, I.C., Vera, R., Lobo de Mena, M., Adeva Alfonso, J., Melian, M., Gallego Jimenez, I., Laquente, B., Fernandez Montes, A., Peinado Martin, P., Carrato Mena, A., Aranda Aguilar, E.

Get full text

533P Oligodendrogliomas: What is the impact after the introduction of the WHO molecular classification? by Salgado, M.A. Vaz, Earl, J., Sanchez, J.M. Sepulveda, Ruano, Y., Gutierrez, J., Pian, H., Ley, L.L., Delgado, M.L. Villamayor, Mena, A. Carrato, Fernandez, E., Martin, M., Monteagudo, R. Ferreiro, Muñoz, F. Longo, Rodriguez, M., Albarrán, V., Perez, J. Pozas, Ballesteros, P. Alvarez, San Roman Gil, M.V., A.H. lain

Get full text

574PInterim quality of life results from a real world European survey on the unmet needs of patients living with metastatic colorectal cancer (mCRC) by Maravic, Z, Wyrwicz, L, Karczmarek-Borowska, B, Horvath, A, Ruiz Casado, A, Carrato Mena, A, Muszbek, N, Rakonczai, P

Get full text

561P - Oncological outcome and safety of bevacizumab (BV) therapy in patients with occlusive colon cancer and self-expandable metal stents (SEMS) by Pacheco-Barcia, V.E., Mondejar, R., Martinez-Saez, O., Munoz, F Longo, Monteagudo, J A Moreno, Rogado, J., Donnay, O., Santander, C., Mena, A Carrato, Bosch, R Colomer

“…Malignant bowel obstruction can occur in 18% of cases. SEMS can be an alternative to surgery. BV has been associated with bowel perforation but data on the…”
Get full text

561POncological outcome and safety of bevacizumab (BV) therapy in patients with occlusive colon cancer and self-expandable metal stents (SEMS) by Pacheco-Barcia, V E, Mondejar, R, Martinez-Saez, O, Munoz, F Longo, Monteagudo, J A Moreno, Rogado, J, Donnay, O, Santander, C, Mena, A Carrato, Bosch, R Colomer

“…Abstract Background Malignant bowel obstruction can occur in 18% of cases. SEMS can be an alternative to surgery. BV has been associated with bowel perforation…”
Get full text

Oncological outcome and safety of bevacizumab (BV) therapy in patients with occlusive colon cancer and self-expandable metal stents (SEMS) by Pacheco-Barcia, V.E., Mondejar, R., Martinez-Saez, O., Munoz, F Longo, Monteagudo, J A Moreno, Rogado, J., Donnay, O., Santander, C., Mena, A Carrato, Bosch, R Colomer

Get full text